Biosimilars : opportunities and risks
BACKGROUND: Biologic therapies are a key component of modern medicine, especially in the treatment of chronic conditions and in particular immune-mediated diseases. Biosimilars are molecularly highly similar variants of biologic therapies approved after patent expiration of the original product.
OBJECTIVES: To provide an overview of the emerging role of biosimilars and present data with respect to efficacy and safety.
CURRENT DATA: Since the approval of human insulin as the first biologic therapy, over 150 biologic therapeutics have been approved in the European Union (EU). Due to the high cost of development and production, biologic therapies place a heavy burden on healthcare systems and, at costs totaling 13.8 billion Euros annually, comprise one third of the annual drug expenditure in Germany. Biosimilars are highly similar versions of already approved biologic therapies that do not have clinically relevant differences with respect to efficacy, safety and immunogenicity, as far as can currently be ascertained. Through competition with the original product, biosimilars have been able to drive down prices and relieve the healthcare system without changing overall efficacy. The potential savings through biosimilars are estimated to be 500 million Euros in Germany alone. Currently, over 50 biosimilars of 16 different biologic therapies are approved in the EU.
CONCLUSIONS: Biosimilars are safe and economical alternatives to biooriginal drugs that can boost access to modern, high-cost therapies and relieve healthcare systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Der Internist - 61(2020), 5 vom: 07. Mai, Seite 522-529 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Biosimilars – Chancen und Risiken |
|---|
| Beteiligte Personen: |
Grieshaber-Bouyer, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 28.05.2020 Date Revised 14.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-020-00784-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309171970 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309171970 | ||
| 003 | DE-627 | ||
| 005 | 20231225133325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-020-00784-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309171970 | ||
| 035 | |a (NLM)32333085 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Grieshaber-Bouyer, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biosimilars |b opportunities and risks |
| 246 | 3 | 3 | |a Biosimilars – Chancen und Risiken |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.05.2020 | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Biologic therapies are a key component of modern medicine, especially in the treatment of chronic conditions and in particular immune-mediated diseases. Biosimilars are molecularly highly similar variants of biologic therapies approved after patent expiration of the original product | ||
| 520 | |a OBJECTIVES: To provide an overview of the emerging role of biosimilars and present data with respect to efficacy and safety | ||
| 520 | |a CURRENT DATA: Since the approval of human insulin as the first biologic therapy, over 150 biologic therapeutics have been approved in the European Union (EU). Due to the high cost of development and production, biologic therapies place a heavy burden on healthcare systems and, at costs totaling 13.8 billion Euros annually, comprise one third of the annual drug expenditure in Germany. Biosimilars are highly similar versions of already approved biologic therapies that do not have clinically relevant differences with respect to efficacy, safety and immunogenicity, as far as can currently be ascertained. Through competition with the original product, biosimilars have been able to drive down prices and relieve the healthcare system without changing overall efficacy. The potential savings through biosimilars are estimated to be 500 million Euros in Germany alone. Currently, over 50 biosimilars of 16 different biologic therapies are approved in the EU | ||
| 520 | |a CONCLUSIONS: Biosimilars are safe and economical alternatives to biooriginal drugs that can boost access to modern, high-cost therapies and relieve healthcare systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biological products | |
| 650 | 4 | |a Biosimilar pharmaceuticals, safety | |
| 650 | 4 | |a Biosimilar pharmaceuticals, treatment outcome | |
| 650 | 4 | |a Drug costs | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 700 | 1 | |a Lorenz, H-M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Internist |d 1960 |g 61(2020), 5 vom: 07. Mai, Seite 522-529 |w (DE-627)NLM000030767 |x 1432-1289 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2020 |g number:5 |g day:07 |g month:05 |g pages:522-529 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-020-00784-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2020 |e 5 |b 07 |c 05 |h 522-529 | ||